These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 24869579

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Frustaci AM, Tedeschi A, Deodato M, Mazzucchelli M, Cairoli R, Montillo M.
    Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Christoforidou A, Kapsas G, Bezirgiannidou Z, Papamichos S, Kotsianidis Ι.
    Turk J Haematol; 2018 May 25; 35(2):147-149. PubMed ID: 29391330
    [No Abstract] [Full Text] [Related]

  • 5. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Wang M, Xu W, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb 25; 22(1):245-9. PubMed ID: 24598688
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ibrutinib-associated T-cell pseudolymphoma.
    Ho AKH, Koh XQ, Liau MMQ, Tan KB, Tan CL.
    Clin Exp Dermatol; 2019 Oct 25; 44(7):828-830. PubMed ID: 30623454
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A mechanism-driven treatment for chronic lymphocytic leukemia?
    Foà R, Guarini A.
    N Engl J Med; 2013 Jul 04; 369(1):85-7. PubMed ID: 23782159
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Wanquet A, Birsen R, Lemal R, Hunault M, Leblond V, Aurran-Schleinitz T.
    Blood; 2016 May 12; 127(19):2356-8. PubMed ID: 26994148
    [No Abstract] [Full Text] [Related]

  • 13. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN, O'Brien S.
    Expert Opin Drug Saf; 2017 Sep 12; 16(9):1079-1088. PubMed ID: 28627951
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
    Famà R, Bomben R, Rasi S, Dal Bo M, Ciardullo C, Monti S, Rossi F, D'Agaro T, Zucchetto A, Gattei V, Gaidano G, Rossi D.
    Blood; 2014 Dec 11; 124(25):3831-3. PubMed ID: 25498455
    [No Abstract] [Full Text] [Related]

  • 17. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A, Brown JR.
    Drugs Aging; 2017 Jul 11; 34(7):509-527. PubMed ID: 28536906
    [Abstract] [Full Text] [Related]

  • 18. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Kaur V, Swami A.
    Ann Hematol; 2017 Jul 11; 96(7):1175-1184. PubMed ID: 28342031
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.